Reverse-Turn Mimetics for AML Treatment via Wnt Pathway Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing bioactive compounds that target the Wnt signaling pathway to suppress acute myeloid leukemia (AML) are limited by low efficacy and scalability, and existing compounds often have high CYP3A4 inhibitory activity and poor hepatic metabolic stability.
Innovation Solution
Development of novel reverse-turn mimetics represented by Formula I, which are highly bioactive, have low CYP3A4 inhibitory activity, and exhibit superior hepatic metabolic stability, allowing for effective inhibition of AML cell proliferation and tumor growth, even at lower doses and with reduced frequency of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional reverse-turn mimetics are used to block Wnt signaling pathway, then some anti-proliferative activity is achieved, but the efficacy is low and the compounds have high CYP3A4 inhibitory activity with poor hepatic metabolic stability
Solution Approach 1:
The patent modifies the chemical structure of reverse-turn mimetics by changing parameters such as the introduction of fluorine atoms at specific positions (e.g., 6-fluoro-5,6,7,8-tetrahydroisoquinolin-2-yl methoxy group), adjustment of substituent groups (R1-R6), and modification of the core scaffold. These parameter changes result in compounds with improved hepatic metabolic stability and reduced CYP3A4 inhibitory activity while maintaining or enhancing anti-proliferative efficacy against AML cells through the Wnt signaling pathway blockade.
2Productivity
If existing compounds are used to suppress AML cell proliferation, then some therapeutic effect is achieved, but the dosage required is high and the treatment frequency is frequent
Solution Approach 1:
The patent employs parameter changes in the molecular structure of reverse-turn mimetics, including modification of hydrophobicity, molecular weight, and functional groups, to optimize the compounds' pharmacokinetic properties. This results in enhanced therapeutic efficacy at lower dosages and reduced treatment frequency, as the modified compounds exhibit improved bioavailability, target binding affinity, and metabolic stability.
3Productivity
If random screening methods are used to discover bioactive compounds, then a number of drugs have been discovered, but the process is time-consuming and the efficacy of discovered compounds varies
Solution Approach 1:
The patent applies preliminary action by pre-designing and synthesizing reverse-turn mimetics with specific structural features known to interact with the Wnt signaling pathway based on prior structural-activity relationship studies. This targeted approach, rather than random screening, allows for more efficient identification of bioactive compounds with desired efficacy profiles, reducing the time and resources required for drug discovery.
Data Source
AI summary
This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method ofpreparing the same, and the use thereofto treat diseases such as cancer, in particular, acute myeloid leukemia.